Pankit Vachhani, MD

Panelists discuss additional data supporting the use of alternative agents and treatment pathways for polycythemia vera (PV), including the role of ropeginterferon alfa-2b (Ropeg alfa-2b) based on findings from the PROUD-PV /CONTINUATION-PV studies.

Panelists discuss the role of JAK inhibition in the treatment of polycythemia vera (PV), focusing on the latest efficacy data for ruxolitinib (RUX) from studies such as RUX vs best available therapy (BAT) in PV and the MAJIC-PV trial, highlighting its impact on treatment outcomes.

Panelists discuss how cytoreductive therapy fits into the treatment paradigm for polycythemia vera (PV), highlighting key findings from the CYTO-PV study and its subanalysis, which inform their treatment decisions for patients with PV.

Panelists discuss how they approach the evaluation and diagnosis of polycythemia vera (PV), including key clinical manifestations, and how they assess disease risk to determine initial treatment strategies based on NCCN guidelines, considering factors that differentiate low-risk from high-risk PV.

Dr. Pankit Vachhani presents key data from the CYTO-PV and MAJIC-PV studies, evaluating the efficacy of ruxolitinib versus best available therapy in patients with polycythemia vera, focusing on clinical outcomes such as cardiovascular risk reduction, hematocrit management, and long-term molecular responses.

Experts discuss how treatments, either monotherapy or combination, may impact the treatment landscape for MF and how they might choose among the new agents.

Panel experts comment on the role of combination therapies in MF and debate if these therapies will be the new standard of care.

Faculty offer insights into the future of PV management as well as unmet needs.

Faculty discuss the best strategies to monitor patients who are receiving treatment of MF as well as commenting on when it might be appropriate to switch therapies.

Expert oncologists provide insights into how they might manage patients who present with anemia and myelofibrosis in their practice.

Overview of the current FDA approved treatment options for the management of myelofibrosis as well as reviewing recent updates from ASH 2023 on the SIMPLIFY and PERSIST trials.

Panel experts comment on the role of transplant in patients with myelofibrosis.

Experts discuss the clinical implications of the MAJIC-PV trial.

Panel experts talk about when to use cytoreductive therapy and which factors influence their treatment selection as well as reviewing how patients with PV are monitored.

Faculty discuss the treatment goals for patients diagnosed with polycythemia vera and review treatment options for managing PV.

Expert oncologists discuss the REVEAL study and provide their thoughts on these data and the impact in clinical practice.

Experts discuss the optimal strategy for NGS testing, which alterations to test for and how to assess for risk when diagnosing and managing patients with polycythemia vera (PV).

Experts explain how polycythemia vera is diagnosed and the typical symptoms a patient may present with.

The hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tract, spleen, and/or liver, caused by an activating KIT mutation in the KIT gene.

Shared closing thoughts on the future treatment landscape for myeloproliferative neoplasms, including future and emerging areas of research and remaining areas of unmet need.

A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.

Focused discussion on emerging trial data surrounding novel, investigational therapies for myelofibrosis.

Expert perspectives on treatment sequencing strategies with JAK inhibitors for myelofibrosis.

Shared insights on monitoring strategies for myelofibrosis, including important considerations for patients receiving treatment with JAK inhibitors.

Panel experts briefly review supporting data for the use of JAK inhibitors in myelofibrosis and discuss the impact of emerging data on the current treatment landscape.

Expert perspectives on how to identify and assess patients with myelofibrosis for transplant therapy.

Comprehensive discussion highlighting diagnostic and molecular testing involved in the diagnosis of myelofibrosis, challenges related to early diagnosis, and consideration factors for assessing prognostic risk.

Shared insight on classification, risk factors, and important biomarkers and pathways in myelofibrosis.

Panel experts share insight regarding prognosis for patients with polycythemia vera and the associated risk for progression to myelofibrosis.

A review of systemic treatment options used in polycythemia vera and the roles these play in the current treatment landscape.